HUMULIN R 100 UNIT — DIN 00586714
INSULIN SEMI SYNTHETIC HUMAN : 100 UNIT · ELI LILLY CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is HUMULIN R?
HUMULIN R 100 UNIT contains INSULIN SEMI SYNTHETIC HUMAN : 100 UNIT. It is listed in the Health Canada Drug Product Database under DIN 00586714, held by ELI LILLY CANADA INC, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 25-May-2026. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is HUMULIN R used for?
HUMULIN (insulin, human biosynthetic) is indicated for the treatment of insulin requiring diabetic patients. HUMULIN-R only should be used for the treatment of emergencies such as diabetic coma and pre-coma and in diabetics undergoing surgery, but not HUMULIN-N, or HUMULIN MIXTURES.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Insulin (Human) cost around the world?
Insulin (Human) is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Norway publishes a max AUP (pharmacy retail); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 41 | 41 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 5 | 6 | NOK███.██ |
| South Africa | single exit price | 1 | 2 | ZAR███.██ |
49 pack listings across 47 brand entries and 3 price bases, refreshed 07 Sep 2026. Ranges span every Insulin (Human) pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Insulin (Human) in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Insulin (Human), across 9 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ELI LILLY CANADA INC | 3 | 2 | HUMULIN R, HUMULIN R (KWIKPEN), HUMULIN R CARTRIDGE | Sourceable in Canada |
| NOVO NORDISK CANADA INC | 2 | 1 | NOVOLIN GE TORONTO, NOVOLIN GE TORONTO PENFILL | Sourceable in Canada |
| BAXTER CORPORATION | 1 | 1 | MYXREDLIN | Sourceable in Canada |
| NOVO NORDISK A/S | 2 | 0 | NOVOLINSET GE TORONTO INJ LIQ 100U/ML, VELOSULIN HUMAN INJ LIQ 100U/ML | No marketed DIN |
| ELI LILLY AND COMPANY LIMITED | 1 | 0 | ILETIN INSULIN REGULAR 100UNIT/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 UNIT |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS ; INTRAVENOUS ; INTRAMUSCULAR |
| Pack configuration (monograph) | HUMULIN R, insulin injection, human biosynthetic (rDNA Origin) REGULAR: Vial HI0210, 10 mL, 100 units/mL. Vial HI0213, 3 mL, 100 units/mL. Cartridge HI0219, 3.0 mL, 100 units/mL, 5 cartridges/box. HUMULIN R KwikPen, insulin injection, human biosynthetic (rDNA Origin) REGULAR: Cartridge and Pen HP8804, 3.0 mL prefilled pen, 100 units/mL, 5 pens/box. HUMULIN N, insulin isophane, human biosynthetic (rDNA Origin) NPH: Vial HI0310, 10 mL, 100 units/mL. Vial HI0313, 3 mL, 100 units/mL. Cartridge HI0319, 3.0 mL, 100 units /mL, 5 cartridges/box. HUMULIN N KwikPen, insulin isophane, human biosynthetic (rDNA Origin) NPH: Cartridge and Pen HP8805, 3.0 mL prefilled pen, 100 units/mL, 5 pens/box. HUMULIN 30/70, 30% insulin injection, 70% insulin isophane, human biosynthetic (rDNA Origin): Vial HI0710, 10 mL, 100 units/mL. Cartridge HI0719, 3.0 mL, 100 units/mL, 5 cartridges/box. HUMULIN cartridges are designed for use with Lilly injector systems. Not all pack sizes and presentations may be marketed. |
| Storage | Prior to first use insulin should be stored in a cold place (2-8°C), preferably in a refrigerator, but not in a freezer. Do not let it freeze or leave it in direct sunlight. Expiration dates are stated on the labels. When in current use, vials, cartridges and prefilled pens should be stored at room temperature and discarded after 28 days. Your unused HUMULIN R cartridges or KwikPens (prefilled pens) should be stored in the refrigerator (2°-8°C). DO NOT FREEZE. The cartridge or KwikPen of insulin that you are currently using does not have to be refrigerated but should be kept at a temperature below 25°C, away from direct heat and sunlight and protected from freezing. The cartridge of insulin currently in use should be left in the pen and may be carried with you. Cartridges or KwikPens in use or not refrigerated should be discarded after 28 days even if they contain insulin. Your unused HUMULIN R vials should be stored in the refrigerator (2°-8°C). DO NOT FREEZE. The vial of insulin that you are currently using does not have to be refrigerated but should be kept at a temperature below 25°C, away from direct heat and sunlight and protected from freezing. Vials in use or not refrigerated should be discarded after 28 days even if they contain insulin. Your unused HUMULIN N cartridges or KwikPens (prefilled pens) should be stored in the refrigerator (2°-8°C). DO NOT FREEZE. The cartridge or KwikPen of insulin that you are currently using does not have to be refrigerated but should be kept at a temperature below 25°C, away from direct heat and sunlight and protected from freezing. The cartridge of insulin currently in use should be left in the pen and may be carried with you. Cartridges or KwikPens in use or not refrigerated should be discarded after 28 days even if they contain insulin. Your unused HUMULIN N vials should be stored in the refrigerator (2°-8°C). DO NOT FREEZE. The vial of insulin that you are currently using does not have to be refrigerated but should be kept at a temperature below 25°C, away from direct heat and sunlight and protected from freezing. Vials in use or not refrigerated should be discarded after 28 days even if they contain insulin. Your unused HUMULIN 30/70 cartridges should be stored in the refrigerator (2°-8°C). DO NOT FREEZE. The cartridge of insulin that you are currently using does not have to be refrigerated but should be kept at a temperature below 25°C, away from direct heat and sunlight and protected from freezing. The cartridge of insulin currently in use should be left in the pen and may be carried with you. Cartridges in use or not refrigerated should be discarded after 28 days even if they contain insulin. Your unused HUMULIN 30/70 vials should be stored in the refrigerator (2°-8°C). DO NOT FREEZE. The vial of insulin that you are currently using does not have to be refrigerated but should be kept at a temperature below 25°C, away from direct heat and sunlight and protected from freezing. Vials in use or not refrigerated should be discarded after 28 days even if they contain insulin. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Insulin (Human) |
|---|---|
| ATC code | A10AB01 |
| AHFS class | 68:20.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00586714 |
|---|---|
| DIN (unpadded, as printed on some documents) | 586714 |
| Brand name | HUMULIN R |
| Generic / active ingredient | INSULIN SEMI SYNTHETIC HUMAN : 100 UNIT |
| Market authorization holder | ELI LILLY CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | A10AB01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10AB |
| Current status | CANCELLED POST MARKET |
| Status date | 25-May-2026 |
| Original market date | 1983-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The dosage should be determined by the physician, according to the requirements of the patient. HUMULIN-R is a clear, colourless solution. It may be administered by subcutaneous, intra-muscular or intravenous injection. HUMULIN-N and HUMULIN MIXTURES are suspensions. They should be administered by subcutaneous injection only. Subcutaneous administration, preferably by the patient, should be in the upper arms, thighs, buttocks or abdomen. Injection sites should be rotated so that the same site is not used more than approximately once a month, in order to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Care should be taken to ensure that a blood vessel has not been entered. The injection site should not be massaged. To prevent the possible transmission of disease, never share a HUMULIN R, HUMULIN N, or HUMULIN 30/70, cartridge or pen, between patients even if the needle on the delivery device is changed.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
HUMULIN (insulin, human biosynthetic) is contraindicated during episodes of hypoglycemia. HUMULIN is contraindicated in patients with hypersensitivity to human insulin or any of its excipients contained in the formulation (unless used as part of a desensitization program). HUMULIN-N, HUMULIN MIXTURES, should not be given intravenously or used for treatment of diabetic coma.
Warnings and precautions
Hypoglycemia is the most common adverse effect of insulin products. Glucose monitoring should be performed for all patients with diabetes mellitus treated with insulins. Uncorrected hypoglycemic or hyperglycemic reactions can cause loss of consciousness, coma or even death. Any transfer of HUMULIN or HUMULIN MIXTURES should be made cautiously and only under medical supervision. Fast-acting insulins should be combined with a longer-acting insulin or insulin infusion pump therapy to maintain adequate glucose control. HUMULIN and HUMULIN MIXTURES should not be mixed with any other insulin unless clearly indicated and done under medical supervision. Under no circumstances should any HUMULIN MIXTURE be given intravenously. Do not use the HUMULIN-N or HUMULIN MIXTURES if you see lumps that float or that stick to the sides of the vial, or if the contents of the vial are clear and remain clear after the bottle is shaken or rotated. NOTE: The contents of the vial or cartridge of HUMULIN-R should be clear. Do not use if cloudy. A few patients who experienced hypoglycemic reactions after being transferred to HUMULIN (insulin, human biosynthetic) have reported that these early warning symptoms were less pronounced than they were with animal-source insulin. As with all insulin therapies, the duration of action of HUMULIN and HUMULIN MIXTURES may vary in different individuals or in the same individual according to dose, injection site, blood flow, temperature and level of physical activity. Hypokalemia is among the potential clinical adverse effects associated with the use of HUMULIN and all other insulin therapies. Stress or concomitant illness, especially infectious and febrile conditions may change insulin requirements. To avoid transmission of disease, a cartridge or prefilled syringe should not be used by more than one person. The number and size of daily doses and the time of administration, as well as diet and exercise, are problems that require direct and continuous medical supervision. Usually, the most satisfactory injection time is before breakfast. Insulin plus Thiazolidinediones (TZDs): TZDs, alone or in combination with other antidiabetic agents (including insulin), can cause heart failure and edema. The combination of insulin with a TZD is not indicated for the treatment of type 2 diabetes mellitus. Please refer to the respective TZD product monograph Warnings and Precautions information when the use of these drugs in combination with any insulin, including HUMULIN R, HUMULIN N or HUMULIN 30/70, is contemplated. Changes in Insulin Regimen / Transferring Patients from Other Insulins: When patients are transferred between different types of insulin products, including animal insulins, the early warning symptoms of hypoglycemia may change or become less pronounced than those experienced with their previous insulin. Transferring a patient to a new type or brand of insulin should be done only under strict medical supervision. Changes in insulin regimen, strength, timing of administration, manufacturer, type (e.g., regular, NPH, or insulin analogs), or method of manufacture (recombinant DNA versus animal source insulin) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of glucose monitoring. Changes in insulin dose or an adjustment in concomitant oral antidiabetic treatment may be needed. If an adjustment is needed, it may be done with the first doses or during the first few weeks or months and under medical supervision.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| HUMULIN R (KWIKPEN) | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | MARKETED | 02415089 |
| HUMULIN R CARTRIDGE | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | MARKETED | 01959220 |
| MYXREDLIN | 1 UNIT | SOLUTION | BAXTER CORPORATION | MARKETED | 02529602 |
| NOVOLIN GE TORONTO | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02024233 |
| ILETIN INSULIN REGULAR 100UNIT/ML | 100 UNIT | LIQUID | ELI LILLY AND COMPANY LIMITED | CANCELLED POST MARKET | 00446564 |
| NOVOLIN GE TORONTO PENFILL | 100 UNIT | SOLUTION | NOVO NORDISK CANADA INC | CANCELLED POST MARKET | 02024284 |
| NOVOLINSET GE TORONTO INJ LIQ 100U/ML | 100 UNIT | LIQUID | NOVO NORDISK A/S | CANCELLED POST MARKET | 02025256 |
| VELOSULIN HUMAN INJ LIQ 100U/ML | 100 UNIT | LIQUID | NOVO NORDISK A/S | CANCELLED POST MARKET | 01986805 |
2 · Same class — other molecules in ATC A10AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Insulin Lispro | ADMELOG · ADMELOG SOLOSTAR · HUMALOG · HUMALOG (CARTRIDGE) · +4 more | 13 | 8 | Yes |
| Insulin Aspart | FIASP · KIRSTY · NOVORAPID · TRURAPI | 11 | 8 | Yes |
| Insulin (Human) | HUMULIN R · HUMULIN R (KWIKPEN) · HUMULIN R CARTRIDGE · ILETIN INSULIN REGULAR 100UNIT/ML · +5 more | 9 | 4 | Yes |
| Insulin Glulisine | APIDRA | 4 | 3 | Yes |
| Insulin (Pork) | HYPURIN REGULAR INSULIN PORK · REGULAR PURIFIED PORK INSULIN INJ | 2 | 1 | Yes |
| Insulin (Beef) | SULPHATED INSULIN INJ LIQ 100U/ML | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10AE | Insulin (Human) · Insulin Degludec · Insulin Degludec And Liraglutide · Insulin Detemir · Insulin Glargine · +2 more | 23 | 15 |
| A10AD | Insulin (Human) · Insulin Aspart · Insulin Lispro | 31 | 9 |
| A10AC | Insulin (Human) · Insulin (Pork) | 13 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is HUMULIN R called?
Also recorded in Canada as: Humulin S (UK), Insulin human (GLOBAL), Insulin Human (US), Insulin Human (UK), Human Insulin (Genetical Recombination) (JP), Regular Insulin (GLOBAL), Soluble Insulin (UK).
The same molecule, Insulin (Human), is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Actrapid HM (ge) | Latin | South Africa |
| Insuman Rapid | Latin | Norway |
| Humulin NPH | Latin | Norway |
| Humulin NPH KwikPen | Latin | Norway |
| Insuman Infusat | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.